Eli Lilly and Company ($LLY) Stock Forecast: Down 6.3% Today

What is Eli Lilly and Company?

Eli Lilly (LLY) is a pharmaceutical company known for its innovative medicines in areas such as diabetes, cancer, and weight loss. The stock had a bearish movement today amidst recent news and market conditions.

Why is Eli Lilly and Company going down?

LLY stock is down 6.3% on Jan 14, 2025 17:45

• Eli Lilly cut its Q4 revenue guidance, expecting around $5.5 billion in sales from weight loss/diabetes drugs, leading to a bearish sentiment among investors.
• The acquisition of Scorpion Therapeutics' early-stage cancer program for $2.5 billion might have raised concerns about the company's future expenses and profitability.
• The comparison with Novo Nordisk as the best weight loss stock for 2025 could have shifted investor focus and triggered profit-taking in Eli Lilly shares.
• Despite the recent decline in stock price, analysts suggest holding onto Eli Lilly due to its robust growth prospects, indicating a potential rebound in the future.

LLY Price Chart

LLY Technical Analysis

LLY News

Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion Sales From Weight Loss/Diabetes Drugs, Stock Tanks - Eli Lilly ( NYSE:LLY )

2024 revenue forecast: $45.0 billion ( +32% YoY ) , below the $45.50 billion consensus. 2025 revenue guidance: $58.0 billion to $61.0 billion, driven by new medicines and global expansions. Get Real-Time News and Alerts for Your Portfolio

https://www.benzinga.com/25/01/42976923/eli-lilly-expects-around-55-billion-sales-from-weight-lossdiabetes-drugs-with-overall-topline-growth-of-32-issues

Eli Lilly ( LLY ) Stock Declines While Market Improves: Some Information for Investors

Eli Lilly (LLY) closed the most recent trading day at $797.48, moving -0.3% from the previous trading session.

https://www.zacks.com/stock/news/2396159/eli-lilly-lly-stock-declines-while-market-improves-some-information-for-investors

Eli Lilly Scoops Up Scorpion Therapeutics' Early-Stage Cancer Program For $2.5 Billion - Eli Lilly ( NYSE:LLY )

Eli Lilly will acquire Scorpion's PI3Kα inhibitor STX-478 for up to $2.5 billion, including a $1 billion upfront payment. Scorpion will spin out a new entity, retaining non-PI3Kα assets, led by its current management team.

https://www.benzinga.com/25/01/42949261/eli-lilly-scoops-up-scorpion-therapeutics-early-stage-cancer-program-for-25-billion

Eli Lilly ( LLY ) Vs Novo Nordisk ( NVO ) : Which is the Best Weight Loss Stock for 2025?

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY) and Novo Nordisk (NVO) stock.

https://www.zacks.com/stock/news/2394756/eli-lilly-lly-vs-novo-nordisk-nvo-which-is-the-best-weight-loss-stock-for-2025

LLY Falls Around 14% in 3 Months: How to Play the Stock

Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.

https://www.zacks.com/stock/news/2394229/lly-falls-around-14-in-3-months-how-to-play-the-stock

Trending Today

XRP ($XRP) Crypto Forecast: Up 11.7% Today

Dogecoin ($DOGE) Crypto Forecast: Up 5.2% Today

Gala ($GALA) Crypto Forecast: Up 7.0% Today

Movement ($MOVE) Crypto Forecast: Down 5.0% Today

Ondo ($ONDO) Crypto Forecast: Down 5.1% Today

Chainlink ($LINK) Crypto Forecast: Up 6.7% Today

Memecoin ($MEME) Crypto Forecast: Up 5.1% Today

Horizen ($ZEN) Crypto Forecast: Up 16.2% Today

Litecoin ($LTC) Crypto Forecast: Up 5.1% Today

Peanut Squirrel ($PNUT) Crypto Forecast: Up 6.2% Today

Eli Lilly and Company Price History

30.09.2024 - LLY Stock was down 8.2%

• Disappointing third-quarter earnings and sales were reported by Eli Lilly, missing estimates for both metrics.
• Sales of key products such as Mounjaro and Zepbound also fell below expectations, contributing to the stock's decline.
• The company's lowered 2024 guidance and the significant hit to profit further fueled negative sentiment among investors, leading to an 11% decline in the stock.
• The market reaction indicates that investors were not pleased with the company's performance and outlook, causing a sharp decline in the stock price.

30.09.2024 - LLY Stock was down 13.6%

• Eli Lilly (LLY) reported Q3 earnings and revenue below estimates, leading to a -22.37% surprise in earnings and a 4.92% miss in revenue.
• The company's third-quarter earnings were impacted by a more than double increase in Mounjaro sales but took a $2.98 billion hit to profit, causing the stock to plummet.
• Despite an impressive 51% year-to-date gain, speculation around a stock split, and focus on tirzepatide medicines like Mounjaro and Zepbound, the missed revenue consensus and lowered annual outlook contributed to the bearish movement.
• Additionally, the release of new data on donanemab potentially providing a path to improved profiles might not have been enough to offset the negative impact of the earnings miss and lowered guidance.

15.10.2024 - LLY Stock was down 5.7%

• Detailed results from the Phase 3 SURMOUNT-1 three-year study for tirzepatide led to investor disappointment, influencing the bearish sentiment towards Eli Lilly.
• Unusual options activity from substantial investors indicated a bearish stance, potentially contributing to the stock's decline.
• Criticism from a humanitarian organization about high insulin prices by insulin manufacturers, including Eli Lilly, raised concerns about regulatory challenges or public backlash.
• Despite weaker sales of Mounjaro and Zepbound in the third quarter, growth opportunities for Eli Lilly suggest that the current bearish movement may be a temporary market reaction rather than a long-term trend.

08.10.2024 - LLY Stock was up 5.1%

• Market whales making bullish bets on LLY options indicate confidence in the company's future prospects.
• The positive sentiment towards high-growth stocks may have spilled over to Eli Lilly, contributing to its bullish movement.
• Analysts assessing Eli Lilly's performance against competitors in the pharmaceutical industry might have highlighted its strengths, boosting investor confidence.
• Overall, the combination of bullish options activity, positive market sentiment, and favorable industry comparisons likely propelled Eli Lilly's stock to a strong bullish movement today.

20.11.2024 - LLY Stock was up 5.2%

• Eli Lilly's stock rose notably following the endorsement from the European Medicines Agency (EMA) panel for expanded use of Omvoh in treating Crohn's Disease, underscoring the company's dedication to developing effective treatments.
• Despite another company's weight loss drug not meeting expectations, Eli Lilly's positive updates overshadowed any potential negativity in the pharmaceutical sector.
• The bearish options trends in Eli Lilly's stock may have been counterbalanced by the favorable endorsement from the CHMP, boosting investor confidence and fueling the upward trend.
• With speculation around the next trillion-dollar company, Eli Lilly's progress in healthcare solutions positions it well for potential future growth and market valuation.

26.10.2024 - LLY Stock was up 5.4%

• The bullish movement in Eli Lilly's stock may be linked to the Biden-Harris Administration's proposed rule to expand coverage of anti-obesity medications for Americans with Medicare and Medicaid, potentially boosting investor confidence in the company's sales and revenue prospects.
• Insider purchases by figures like Ralph Alvarez and J. Erik Fyrwald could have also positively influenced market sentiments around Eli Lilly, with insider buying typically regarded as a signal of confidence in the company's future.
• Despite recent challenges and a decline in stock price over the past month, these insider purchases and favorable regulatory updates appear to have eclipsed previous concerns, resulting in the significant bullish movement in Eli Lilly's stock today.

14.00.2025 - LLY Stock was down 5.1%

• Despite the overall market decline, Eli Lilly's stock price increased by +1.07%.
• The acquisition of Scorpion Therapeutics' early-stage cancer program for $2.5 billion could have positively influenced investor sentiment towards Eli Lilly.
• The anticipation of weight loss resolutions in the new year may have contributed to the optimistic outlook for Eli Lilly's stock.
• Investors holding onto Eli Lilly stock despite a recent 14% fall in the past 3 months indicates confidence in the company's future growth prospects.

31.09.2024 - LLY Stock was up 7.0%

• Despite missing Q3 earnings and revenue estimates, Eli Lilly's stock saw a strong bullish movement, showcasing resilience in the market.
• The bearish movement caused by the company cutting its 2024 forecast was overshadowed by the positive market sentiment towards the pharmaceutical industry as a whole.
• Investors may be focusing on the company's impressive year-to-date gain and potential stock split speculation, leading to increased buying interest despite the recent setbacks in earnings and guidance.
• The overall bullish market movement and positive sentiment towards pharmaceutical companies could have contributed to Eli Lilly's stock outperforming expectations today.

31.09.2024 - LLY Stock was up 6.9%

• Despite missing Q3 earnings and revenue estimates, Eli Lilly's stock saw a strong bullish movement, showcasing resilience in the face of disappointing financial results.
• The market may have reacted positively due to the anticipation of a potential stock split, fueled by the company's impressive 51% year-to-date gain.
• The overall bullish market movement could be attributed to investors focusing on the long-term growth prospects of Eli Lilly, overlooking the short-term setbacks in the quarterly results.
• It's possible that investors are optimistic about the future pipeline of drugs and treatments from Eli Lilly, leading to increased confidence in the company's ability to rebound from the recent financial challenges.

20.10.2024 - LLY Stock was up 5.2%

• Eli Lilly's stock surged after announcing positive Phase 2 results for muvalaplin, an investigational drug that showed promising efficacy in reducing sticky cholesterol levels by almost 86%.
• Investor sentiment was further boosted by a notable endorsement on a financial media show, where the recommendation to buy Eli Lilly stock was made, citing its potential despite being previously unpopular.
• The detailed Phase 3 data release showing impressive results from a study of tirzepatide also contributed to the positive market response, indicating strong growth prospects for Eli Lilly in the pharmaceutical sector.

14.00.2025 - LLY Stock was down 6.3%

• Eli Lilly cut its Q4 revenue guidance, expecting around $5.5 billion in sales from weight loss/diabetes drugs, leading to a bearish sentiment among investors.
• The acquisition of Scorpion Therapeutics' early-stage cancer program for $2.5 billion might have raised concerns about the company's future expenses and profitability.
• The comparison with Novo Nordisk as the best weight loss stock for 2025 could have shifted investor focus and triggered profit-taking in Eli Lilly shares.
• Despite the recent decline in stock price, analysts suggest holding onto Eli Lilly due to its robust growth prospects, indicating a potential rebound in the future.

09.07.2024 - LLY Stock was up 5.5%

• Strong earnings for the second quarter boosted Eli Lilly's stock, signaling a positive outlook for performance and growth.
• Investor interest in the healthcare sector, which includes Eli Lilly, has been growing as capital flows from high-growth and tech stocks to more stable industries during market uncertainties.
• The confidence in Eli Lilly's stock may stem from investors turning to healthcare investments for their resilience and consistent demand, irrespective of economic fluctuations.
• Despite concerns about healthcare sector valuations and potential regulatory changes post the upcoming presidential election, Eli Lilly's robust earnings report appears to have overshadowed these apprehensions and contributed to the stock's bullish trend.